Literature DB >> 15067363

Germinated barley foodstuff prolongs remission in patients with ulcerative colitis.

Hiroyuki Hanai1, Osamu Kanauchi, Keiichi Mitsuyama, Akira Andoh, Ken Takeuchi, Iida Takayuki, Yoshio Araki, Yoshihide Fujiyama, Atsushi Toyonaga, Michio Sata, Atsushi Kojima, Masanobu Fukuda, Tadao Bamba.   

Abstract

Germinated barley foodstuff (GBF) is a prebiotic which increases luminal butyrate production by modulating the microfloral distribution. GBF has been shown to reduce both clinical activity and mucosal damage in active ulcerative colitis (UC) with mild to moderate activity. However, the efficacy of GBF in patients with UC during the remission stage is unknown. The aim of this study was to investigate the efficacy of GBF as a maintenance therapy in patients with UC while in remission. Fifty-nine patients with UC in remission according to Rachmilewitz's clinical activity index (CAI) score of </=4 were enrolled and divided into two groups, control (n=37) and GBF (n=22). Patients in the control group were given conventional treatment alone for 12 months, while patients in the GBF group received conventional therapy plus 20 g of GBF daily. The response to treatments was assessed by monitoring the CAI and endoscopic score according to Matts. Significantly better CAI values were seen in the GBF group at 3, 6, and 12 months compared with the values in the control group. The cumulative recurrence rate in the GBF group with steroid tapering treatment was significantly lower compared with the value in the control group. No side effects related to GBF were observed. GBF appeared to be effective and safe as a maintenance therapy to taper steroid dose and prolong remission in patients with UC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067363

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  37 in total

Review 1.  Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease.

Authors:  Akira Andoh; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 2.  Probiotics and prebiotics in chronic inflammatory bowel diseases.

Authors:  Julia B Ewaschuk; Levinus A Dieleman
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

Review 3.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 4.  Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.

Authors:  Aonghus Lavelle; Harry Sokol
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-19       Impact factor: 46.802

Review 5.  Complementary Therapies in Inflammatory Bowel Diseases.

Authors:  Henit Yanai; Nir Salomon; Adi Lahat
Journal:  Curr Gastroenterol Rep       Date:  2016-12

Review 6.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

Review 7.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

8.  Effects of an Oral Supplementation of Germinated Barley Foodstuff on Serum CRP Level and Clinical Signs in Patients with Ulcerative Colitis.

Authors:  Zeinab Faghfoori; Rahebeh Shakerhosseini; Lida Navai; Mohammad Hossein Somi; Zeinab Nikniaz; Alireza Abadi
Journal:  Health Promot Perspect       Date:  2014-07-12

9.  Eubacterium limosum ameliorates experimental colitis and metabolite of microbe attenuates colonic inflammatory action with increase of mucosal integrity.

Authors:  Osamu Kanauchi; Masanobu Fukuda; Yoshiaki Matsumoto; Shino Ishii; Toyokazu Ozawa; Makiko Shimizu; Keiichi Mitsuyama; Akira Andoh
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

Review 10.  Environmental risk factors for inflammatory bowel diseases: Evidence based literature review.

Authors:  Ayokunle T Abegunde; Bashir H Muhammad; Owais Bhatti; Tauseef Ali
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.